Elanco Animal Health hopes thousands of studies - and the need to feed the world - will help Posilac make a comeback.
 
That’s the trade name for the recombinant Bovine Somatotropin (rBST) product marketed in the United States for the last 16 years, 15 of them by Monsanto. A flurry of bad publicity caused many retailers, supermarket chains, and ultimately bottlers and cooperatives to reject milk from cows treated with the hormone; in August 2008, Monsanto sold the product—both its assets and liabilities—to Elanco parent company Eli Lilly for $300 million.